"The FTC alleges that PBMs engage in anticompetitive practices by using restrictive formularies and high rebate demands from manufacturers, inflating drug prices and limiting access to insulin."
"Lucas Morgan notes that the momentum currently favors the FTC, highlighting the detailed evidence they possess against PBMs and the public's desire to lower medication costs, particularly for insulin."
Collection
[
|
...
]